Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAAA | Q02083 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.59 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 3/20 | 0.53 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.50 |
| ▸ | RAD52 | P43351 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | FAAH | O00519 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | ACHE | P22303 | 6/20 | 0.48 |
| ▸ | DGKA | P23743 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1836015 | 1.00 | NAAA (0.59) | NAAAALDH1A1EPHX1TSHRHCAR2 | |
| SCHEMBL1836808 | 1.00 | NAAA (0.59) | NAAAALDH1A1EPHX1TSHRHCAR2 | |
| SCHEMBL1836973 | 1.00 | NAAA (0.59) | NAAAALDH1A1EPHX1TSHRHCAR2 | |
| SCHEMBL448327 | 1.00 | NAAA (0.59) | NAAAALDH1A1EPHX1TSHRHCAR2 | |
| SCHEMBL1837624 | 1.00 | NAAA (0.59) | NAAAALDH1A1EPHX1TSHRHCAR2 | |
| SCHEMBL1839333 | 1.00 | NAAA (0.59) | NAAAALDH1A1EPHX1TSHRHCAR2 | |
| SCHEMBL1837793 | 1.00 | NAAA (0.59) | NAAAALDH1A1EPHX1TSHRHCAR2 | |
| SCHEMBL1840756 | 1.00 | NAAA (0.59) | NAAAALDH1A1EPHX1TSHRHCAR2 | |
| SCHEMBL1835018 | 1.00 | NAAA (0.59) | NAAAALDH1A1EPHX1TSHRHCAR2 | |
| SCHEMBL1842169 | 1.00 | NAAA (0.59) | NAAAALDH1A1EPHX1TSHRHCAR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3838892-B1 | METHOD FOR PRODUCING ISOCYANATE | ASAHI CHEMICAL IND (JP) | 2022-10-12 | — | — | EP | disclosed |
| EP-3293173-B1 | METHOD FOR PRODUCING ISOCYANATE | ASAHI CHEMICAL IND (JP) | 2021-07-28 | — | — | EP | disclosed |
| EP-3838892-A1 | METHOD FOR PRODUCING ISOCYANATE | Asahi Kasei Kabushiki Kaisha (JP) | 2021-06-23 | — | — | EP | disclosed |
| EP-2980066-B1 | METHOD FOR PRODUCING ISOCYANATE | ASAHI CHEMICAL IND (JP) | 2021-04-21 | — | — | EP | disclosed |
| US-10544154-B2 | Opioid receptor antagonist prodrugs | NIRSUM LABORATORIES, INC. (US) | 2020-01-28 | — | — | US | disclosed |
| US-20190308989-A1 | OPIOID RECEPTOR ANTAGONIST PRODRUGS | NIRSUM LABORATORIES, INC. | 2019-10-10 | — | — | US | disclosed |
| EP-3153499-B1 | METHOD FOR PRODUCING N-SUBSTITUTED CARBAMIC ACID ESTER | ASAHI CHEMICAL IND (JP) | 2018-09-19 | — | — | EP | disclosed |
| EP-3293173-A1 | METHOD FOR PRODUCING ISOCYANATE | Asahi Kasei Kabushiki Kaisha (JP) | 2018-03-14 | — | — | EP | disclosed |
| EP-2322504-B9 | PROCESS FOR THE PREPARATION OF N-SUBSTITUTED CARBAMIC ACID ESTER AND PROCESS FOR THE PREPARATION OF ISOCYANATE USING THE N-SUBSTITUTED CARBAMIC ACID ESTER | ASAHI CHEMICAL IND (JP) | 2017-09-06 | — | — | EP | disclosed |
| US-9714215-B2 | Method for producing isocyanate | ASAHI KASEI CHEMICALS CORPORATION (JP) | 2017-07-25 | — | — | US | disclosed |
| US-8658819-B2 | N-substituted carbamic acid ester production method, isocyanate production method using such N-substituted carbamic acid ester, and composition for transfer and storage of N-substituted carbamic acid ester comprising N-substituted carbamic acid ester and aromatic hydroxy compound | ASAHI KASEI CHEMICALS CORPORATION (JP) | 2014-02-25 | — | — | US | disclosed |
| CN-102386442-A | Nonaqueous electrolyte and nonaqueous electrolyte battery | SONY CORP | 2012-03-21 | — | — | CN | disclosed |
| US-20120052374-A1 | NONAQUEOUS ELECTROLYTE AND NONAQUEOUS ELECTROLYTE BATTERY | SONY CORPORATION (JP) | 2012-03-01 | — | — | US | disclosed |
| US-20110160476-A1 | N-Substituted Carbamic Acid Ester Production Method and Isocyanate Production Method Using the N-Substituted Carbamic Acid Ester | ASAHI KASEI CHEMICALS CORPORATION (JP) | 2011-06-30 | — | — | US | disclosed |
| US-20110133121-A1 | N-Substituted Carbamic Acid Ester Production Method, Isocyanate Production Method Using Such N-Substituted Carbamic Acid Ester, And Composition For Transfer And Storage Of N-Substituted Carbamic Acid Ester Comprising N-Substituted Carbamic Acid Ester and Aromatic Hydroxy Compound | ASAHI KASEI CHEMICALS CORPORATION (JP) | 2011-06-09 | — | — | US | disclosed |
| EP-2322504-A1 | PROCESS FOR THE PREPARATION OF N-SUBSTITUTED CARBAMIC ACID ESTER AND PROCESS FOR THE PREPARATION OF ISOCYANATE USING THE N-SUBSTITUTED CARBAMIC ACID ESTER | Asahi Kasei Chemicals Corporation (JP) | 2011-05-18 | — | — | EP | disclosed |
| US-7157442-B2 | Antibacterial compound | SANKYO COMPANY, LIMITED (JP) | 2007-01-02 | — | — | US | disclosed |
| EP-1209166-B1 | NOVEL A-500359 DERIVATIVES | SANKYO CO (JP) | 2004-03-31 | — | — | EP | disclosed |
| US-20030171330-A1 | Antibacterial compound | SANKYO COMPANY, LIMITED (JP) | 2003-09-11 | — | — | US | disclosed |
| EP-1209166-A1 | NOVEL A-500359 DERIVATIVES | Sankyo Company, Limited (JP) | 2002-05-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110133121-A1 | N-Substituted Carbamic Acid Ester Production Method, Isocyanate Production Method Using Such N-Substituted Carbamic Acid Ester, And Composition For Transfer And Storage Of N-Substituted Carbamic Acid Ester Comprising N-Substituted Carbamic Acid Ester and Aromatic Hydroxy Compound | CPS1, ALKBH3, RCC1 | NAAA 57/4885ALDH1A1 1568/4885EPHX1 1711/4885 |
| US-20190308989-A1 | OPIOID RECEPTOR ANTAGONIST PRODRUGS | OPRM1, OPRK1, OPRL1 | NAAA 483/4885ALDH1A1 725/4885EPHX1 1341/4885 |
| US-20030171330-A1 | Antibacterial compound | TLR1, MPO, O60361 | NAAA 1397/4885ALDH1A1 356/4885EPHX1 3783/4885 |
| US-10544154-B2 | Opioid receptor antagonist prodrugs | OPRM1, OPRK1, OPRL1 | NAAA 483/4885ALDH1A1 725/4885EPHX1 1341/4885 |
| US-20110160476-A1 | N-Substituted Carbamic Acid Ester Production Method and Isocyanate Production Method Using the N-Substituted Carbamic Acid Ester | ALKBH3, CPS1, APEH | NAAA 4/4885ALDH1A1 574/4885EPHX1 533/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.